• 1
    El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003; 139: 817-823.
  • 2
    Moore SW, Millar AJ, Hadley GP, et al. Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence. Cancer. 2004; 101: 642-649.
  • 3
    Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005; 54: 419-425.
  • 4
    Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005; 41: 707-716.
  • 5
    Huo TI, Lee SD, Wu JC. Staging for hepatocellular carcinoma: look for a perfect classification system. J Hepatol. 2004; 40: 1041-1042.
  • 6
    Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005; 54: 411-418.
  • 7
    Guglielmi A, Ruzzenente A, Pachera S, et al. Comparison of 7 staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008; 103: 597-604.
    Direct Link:
  • 8
    Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-1236.
  • 9
    Camma C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther. 2008; 28: 62-75.
  • 10
    Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology. 2001; 34: 529-534.
  • 11
    Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000; 31: 840-845.
  • 12
    Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004; 40: 1396-1405.
  • 13
    Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of 3 staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol. 2005; 100: 1764-1771.
    Direct Link:
  • 14
    Chen CH, Hu FC, Huang GT, et al. Applicability of staging systems for patients with hepatocellular carcinoma depends on treatment method - Analysis of 2010 Taiwanese patients. Eur J Cancer. 2009; 45: 1630-1639.
  • 15
    Huang YH, Chen CH, Chang TT, et al. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol. 2005; 20: 765-771.
  • 16
    Lei HJ, Chau GY, Lui WY, et al. Prognostic value and clinical relevance of the 6th edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg. 2006; 203: 426-435.
  • 17
    Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma Conclusions of the Barcelona-2000 EASL conference European Association for the Study of the Liver. J Hepatol. 2001; 35: 421-430.
  • 18
    Grant BF, Fufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1998; 8: 12-25.
  • 19
    Huo TI, Lin HC, Lee FY, et al. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int. 2006; 26: 55-61.
  • 20
    Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998 Hepatology. 2002; 35: 716-721.
  • 21
    Kikuchi LO, Paranagua-Vezozzo DC, Chagas AL, et al. Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. J Clin Gastroenterol. 2009; 43: 191-195.
  • 22
    Liver including intrahepatic bile ducts. In: GreeneF, PageD, FlemingI, eds. American Joint Committee on cancer staging manual. 6th ed. New York: Springer; 2002: 131-144.
  • 23
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699.
  • 24
    Huo TI, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006; 101: 975-982.
    Direct Link:
  • 25
    Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer. 2006; 107: 141-148.
  • 26
    Hosmer DW, Hosmer T, Le Cessie S, et al. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997; 16: 965-980.
  • 27
    Feinsten AR. Clinical biostatistics XVI. The process of prognostic stratification. Clin Pharmacol Ther. 1972; 13: 609-624.
  • 28
    Foster MR. Key concepts in model selection: Performance and generalizability. J Math Psychol. 2000; 44: 205-231.
  • 29
    Huo TI, Hsia CY, Huang YH, et al. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and 5 cancer staging systems. J Clin Gastroenterology. 2009; 43: 773-781.
  • 30
    Kudo M, Okanoue T; Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007; 72( suppl 1): 2-15.
  • 31
    Huo TI, Lin HC, Hsia CY, et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol. 2007; 102: 1920-1930.
    Direct Link:
  • 32
    Farinati F, Sergio A, Baldan A, et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer. 2009; 9: 33.
  • 33
    Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009; 115: 1914-1923.
  • 34
    Yen YH, Changchien CS, Wang JH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009; 41: 431-441.
  • 35
    Cho YK, Chung JW, Kim JK, et al. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer. 2008; 112: 352-361.
  • 36
    Minagawa M, Ikai I, Matsuyama Y, et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007; 245: 909-922.
  • 37
    Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl. 2004; 10( 2 suppl 1): S74-S80.